A series of cardiometabolic-related news items has been observed from Novo Nordisk, Lilly, and GSK. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: Gubra received a $50M milestone payment from AbbVie (view press release), and Caliway Biopharmaceuticals received IND clearance and IRB approval for its small molecule lipolysis drug (view press release). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Abbott, AstraZeneca, Lilly, Google, Revier Therapeutics, and Haisco Pharmaceutical. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Roche/Hanmi, Lilly, Lexicon, and Biomea Fusion. Below, FENIX provides highlights and insights for the respective news items.
Two cardiometabolic-related news items have been observed: CureGene Pharmaceutical dosed the first patient in its FIH THR-β agonist study (view press release; view CT.gov record), and a study was conducted comparing compounded retatrutide to non-compounded retatrutide, tirzepatide, and semaglutide (view article). Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Roche/Genentech, Lilly, and Hansoh Pharmaceuticals. Below, FENIX provides highlights and insights for the respective news items.
In the twelfth installment of FENIX’s Obesity Spotlight Series, FENIX asks a provocative question: In today’s obesity market, who will be the next Sanofi? Once a diabetes powerhouse, Sanofi missed both the SGLT2i and GLP-1RA waves, and with the modern-day obesity market projected to exceed $150B by 2035 (view article), the company now finds itself on the sidelines of arguably the biggest growth opportunity in the industry’s history. This Spotlight examines how Sanofi’s past strategic mishaps transformed a potential contender into an observer and which other major pharmas may now be drifting toward the same fate.
Amylyx Pharmaceuticals announced positive topline results from the Ph3 LUCIDITY trial (view CT.gov record) evaluating the efficacy and safety of 90mg avexitide (QD SC GLP-1R antagonist) in participants with post-bariatric hypoglycemia (PBH) following Roux-en-Y gastric bypass (RYGB) surgery (a common type of bariatric surgery). Below, FENIX provides highlights and insights from the results.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, MiniMed, Arrowhead Pharmaceuticals, Sandoz/Henlius, and AstraZeneca. Below, FENIX provides highlights and insights for the respective news items.
Skye Bioscience and Redx Pharma announced they have entered into a definitive transaction agreement, under which Skye will acquire Redx. Skye hosted an associated webcast discussing the transaction (view slides). The combined company plans to operate under the name Fibrx Therapeutics and trade on Nasdaq. Below, FENIX provides highlights and insights into the agreement.